Q1 EPS Estimate for Theravance Biopharma Boosted by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research lifted their Q1 2027 earnings per share estimates for shares of Theravance Biopharma in a note issued to investors on Wednesday, April 23rd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.40) per share for the quarter, up from their previous estimate of ($0.41). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's FY2027 earnings at ($0.77) EPS.

Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $11.33.

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded down $0.25 during trading on Monday, reaching $9.50. 223,966 shares of the company's stock were exchanged, compared to its average volume of 280,405. The firm has a market cap of $475.01 million, a price-to-earnings ratio of -9.41 and a beta of 0.14. The company's 50-day moving average is $9.10 and its two-hundred day moving average is $9.22. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares in the company, valued at approximately $3,330,342. This trade represents a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.90% of the company's stock.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently added to or reduced their stakes in TBPH. Newtyn Management LLC increased its holdings in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after purchasing an additional 258,337 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares in the last quarter. Millennium Management LLC increased its stake in shares of Theravance Biopharma by 71.1% during the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company's stock valued at $1,815,000 after acquiring an additional 80,140 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in Theravance Biopharma by 9.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock worth $7,847,000 after purchasing an additional 69,178 shares in the last quarter. Finally, Trexquant Investment LP lifted its position in Theravance Biopharma by 50.7% in the fourth quarter. Trexquant Investment LP now owns 151,083 shares of the biopharmaceutical company's stock worth $1,422,000 after purchasing an additional 50,826 shares during the period. Institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.